Luminous mitochondria undergoing quality control as NAD+ and MOTS-c signals support cellular aging
| | |

Spermidine and the Autophagy Switch: What 2026 Science Says About the Polyamine That May Mimic Caloric Restriction

Spermidine triggers autophagy, the cell’s recycling system, and a 20 year Austrian cohort linked higher dietary intake to roughly 5 fewer years of mortality. Inside the Frank Madeo Graz research,…

Healthcare AI prediction versus next step for patients | Healthcare Discovery
| | |

The First RAS Inhibitor to Beat Pancreatic Cancer: What Daraxonrasib’s Phase 3 Survival Data Means for Oncology

Revolution Medicines’ daraxonrasib achieved a median overall survival of 13.2 months versus 6.7 months for chemotherapy in previously treated metastatic pancreatic cancer, a 60 percent reduction in the risk of…

Senolytic therapy targeting senescent zombie cells in aging tissue during 2026 longevity clinical trials
| | |

Senolytics in 2026: How the Science of Killing Zombie Cells Reached Its First Human Proof of Concept

A decade of senolytic research is converging into something new. Inside the Mayo Clinic dasatinib quercetin work, the AFFIRM-LITE fisetin trial, Rubedo’s March 2026 Phase 1 readout of RLS-1496, and…

Diet reverses biological age in older adults nutrition longevity study | Healthcare Discovery
| |

Young Blood Revisited: Inside the 2026 Trials Testing Plasma Exchange and Rejuvenation Factors

A decade after parabiosis lit up the longevity field, the science of young blood has matured into rigorous plasma exchange trials, recombinant rejuvenation factors, and a quietly revealing exercise literature….

Healthcare Discovery PEARL trial rapamycin human aging results showing older adults in a clinical longevity research setting
| | |

The PEARL Trial Is In: What Low-Dose Rapamycin Actually Did to Human Aging Over 48 Weeks

The most anticipated longevity drug trial in a generation has delivered its full one-year results. Here is what rapamycin actually did to lean muscle, pain, biological age, and overall healthspan…

Healthcare Discovery MechanoAge breast cancer AI mechanical age risk showing cells measured in a microfluidic diagnostic platform
| | |

Your Cells Have a Mechanical Age, and AI Can Now Read It to Predict Breast Cancer Risk

A UC Berkeley and City of Hope team published a landmark AI platform called MechanoAge in Lancet’s eBioMedicine that measures the physical stress-response of individual breast cells to identify cancer…

AI emergency room diagnosis Harvard study 2026 | Healthcare Discovery
| | |

AI Is Now Building Drugs That Target Aging Itself: Inside the Longevity Board and the New Science of Healthspan Medicine

A Nobel laureate on its board. The world’s largest pharmaceutical company as a founding partner. And a scientific mission to build drugs that target aging itself. Inside Insilico Medicine’s Longevity…

Senolytic therapy targeting senescent zombie cells in aging tissue during 2026 longevity clinical trials
| | |

Senolytics in 2026: Inside the Clinical Trials Targeting Zombie Cells to Extend Healthy Lifespan

More than 30 senolytic and senomorphic clinical trials are now active, spanning diabetic macular edema, pulmonary fibrosis, osteoarthritis, and frailty. Inside the science of zombie cells, the first-generation compounds from…

Healthcare Discovery nasal spray brain aging Texas A&M extracellular vesicles 2026 showing vesicles reaching the hippocampus
| | |

A Nasal Spray That Reverses Brain Aging: The Texas A&M Breakthrough Reshaping Alzheimer’s Research

A two-dose nasal spray built from human neural stem cell-derived particles silenced the inflammation signals that drive cognitive decline, restored memory in aged mice, and is now being positioned for…

Luminous mitochondria undergoing quality control as NAD+ and MOTS-c signals support cellular aging
| |

The Mitochondrial Decade: Urolithin A, NAD+, MOTS-c, and the 2026 Science of Cellular Aging

In 2026, mitochondria have moved from a footnote in biology textbooks to the central organelle of aging research. From urolithin A’s mitophagy revolution to new NAD+ trials, MOTS-c, and the…